Morgan Stanley Nanobiotix S.A. Call Options Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBTX
# of Institutions
13Shares Held
9.31MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$30.3 Million7.7% of portfolio
-
Baillie Gifford & CO2.87MShares$15.5 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$2.99 Million0.08% of portfolio
-
Black Rock Inc. New York, NY253KShares$1.37 Million0.0% of portfolio
-
Ubs Group Ag3.1KShares$16,7090.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $188M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...